Changes in therapeutic strategy in metastatic castration resistant prostate cancer between 2012 and 2014 from the French nationwide claims database

被引：0
|
作者：
Thurin, Nicolas H. [1 ]
Rouyer, Magali [1 ]
Jove, Jeremy [1 ]
Gross-Goupil, Marine [2 ]
Haaser, Thibaud [2 ]
Rebillard, Xavier [3 ]
Soulie, Michel [4 ]
de Pouvourville, Gerard [5 ]
Capone, Camille [6 ]
Pierres, Marie [6 ]
Lamarque, Stephanie [1 ]
Bignon, Emmanuelle [1 ]
Droz-Perroteau, Cecile [1 ]
Moore, Nicholas [1 ,2 ]
Blin, Patrick [1 ]
机构：
[1] Univ Bordeaux, Bordeaux PharmacoEpi, INSERM, CIC1401, Bordeaux, France
[2] CHU Bordeaux, Bordeaux, France
[3] Clin Beau Soleil, Montpellier, France
[4] CHU Toulouse, Toulouse, France
[5] ESSEC, Cergy Pontoise, France
[6] Janssen, Issy Les Moulineaux, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4343
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [1] Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Gross-Goupil, Marine
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Capone, Camille
    Bazil, Marie-Laure
    Messaoudi, Fatiha
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (09) : 1139 - 1145
  • [2] Castration-resistant prostate cancer: What therapeutic strategy in 2014?
    Pignot, G.
    PROGRES EN UROLOGIE, 2014, 24 (03): : F73 - F79
  • [3] Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database
    Thurin, Nicolas H.
    Rouyer, Magali
    Gross-Goupil, Marine
    Rebillard, Xavier
    Soulie, Michel
    Haaser, Thibaud
    Roumiguie, Mathieu
    Le Moulec, Sylvestre
    Capone, Camille
    Pierres, Marie
    Lamarque, Stephanie
    Jove, Jeremy
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    CANCER EPIDEMIOLOGY, 2020, 69
  • [4] Validation of a complex algorithm for the diagnosis of metastatic castration-resistant prostate cancer within a claims database
    Thurin, Nicolas
    Rouyer, Magali
    Gross-Goupil, Marine
    Soulie, Michel
    Le Moulec, Sylvestre
    De Beaucoudrey, Ludovic
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Jove, Jeremy
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 165 - 165
  • [5] METASTATIC CASTRATION RESISTANT PROSTATE CANCER TREATMENT PATTERNS CHANGES WITH THE INTRODUCTION OF ABIRATERONE IN 2012 IN QUEBEC
    Lahcene, H.
    Aprikian, A.
    Vanhuyse, M.
    Bladou, F.
    Prevost, N.
    Hu, J.
    Cury, F.
    Kassouf, W.
    Perreault, S.
    Dragomir, A.
    VALUE IN HEALTH, 2017, 20 (05) : A124 - A124
  • [6] Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new-user design in the French nationwide claims database
    Thurin, Nicolas H.
    Rouyer, Magali
    Gross-Goupil, Marine
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    De Pouvourville, Gerard
    Messaoudi, Fatiha
    Demnati, Hind Stitou El Amine
    Bignon, Emmnuelle
    Jove, Jeremy
    Lamarque, Stephanie
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 249 - 249
  • [7] EFFECTIVENESS AND MEDICAL COSTS OF ABIRATERONE ACETATE VERSUS DOCETAXEL IN FIRST-LINE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM THE FRENCH NATIONWIDE CLAIMS DATABASE (SNDS): CAMERRA STUDY
    Thurin, N.
    Rouyer, M.
    Gross-Goupil, M.
    Haaser, T.
    Rebillard, X.
    Soulie, M.
    Messaoudi, F.
    Capone, C.
    Bignon, E.
    Lamarque, S.
    Jove, J.
    Droz-Perroteau, C.
    Moore, N.
    de Pouvourville, G.
    Blin, P.
    VALUE IN HEALTH, 2020, 23 : S424 - S424
  • [8] Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new user design in the French nationwide claims database.
    Gross-Goupil, Marine
    Thurin, Nicolas H.
    Rouyer, Magali
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Messaoudi, Fatiha
    Capone, Camille
    Bignon, Emmanuelle
    Jove, Jeremy
    Lamarque, Stephanie
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Current therapeutic options in metastatic castration-resistant prostate cancer
    Ingrosso, Gianluca
    Detti, Beatrice
    Scartoni, Daniele
    Lancia, Andrea
    Giacomelli, Irene
    Baki, Muhammed
    Carta, Giulio
    Livi, Lorenzo
    Santoni, Riccardo
    SEMINARS IN ONCOLOGY, 2018, 45 (5-6) : 303 - 315
  • [10] Treatment patterns of castration-resistant prostate cancer: A retrospective claims database analysis
    Burton, Tanya
    Teitelbaum, April H.
    Bui, Cat N.
    Spalding, James Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
12345